会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Sugar chain containing 4-position halogenated galactose and application thereof
    • 含有4-位卤代半乳糖的糖链及其应用
    • US08148112B2
    • 2012-04-03
    • US11815329
    • 2006-02-14
    • Shin-Ichiro NishimuraNoriko NagahoriTomoki HamamotoKiyoshi OkuyamaToshitada Noguchi
    • Shin-Ichiro NishimuraNoriko NagahoriTomoki HamamotoKiyoshi OkuyamaToshitada Noguchi
    • C12P19/50C12P19/52C12P19/26C07H15/00C07H5/04C07H5/06C08B37/00
    • C12P19/32C07H15/08
    • The present invention is directed to, for example, an oligosaccharide having at an end thereof a 4-position halogenated galactose residue represented by formula (I): (wherein X represents a halogen atom, and R represents a monosaccharide, an oligosaccharide, or a carrier), a transferase inhibitor containing the oligosaccharide, and a method for inhibiting sugar chain elongation reaction in the presence of glycosyltransferase, the method including employing the inhibitor. The invention also provides a method for producing a 4-position halogenated galactose sugar nucleotide represented by formula (II): (wherein each of R1 to R3 represents a hydroxyl group, an acetyl group, a halogen atom, or a hydrogen atom; X represents a halogen atom; and M represents a hydrogen ion or a metal ion), wherein the method employs bacterium-derived galactokinase and bacterium-derived hexose-1-phosphate uridylyltransferase. The invention is also directed to a sugar chain containing 4-position halogenated galactose envisaged to be employed as drugs and other materials, and to applications of the compound.
    • 本发明涉及例如末端具有由式(I)表示的4位卤代半乳糖残基的寡糖:(其中X表示卤素原子,R表示单糖,寡糖或 载体),含有寡糖的转移酶抑制剂,以及在糖基转移酶存在下抑制糖链延长反应的方法,该方法包括使用该抑制剂。 本发明还提供了由式(II)表示的4-位卤代半乳糖糖核苷酸的制备方法:(式中,R 1〜R 3各自表示羟基,乙酰基,卤素原子或氢原子; X表示 卤素原子; M表示氢离子或金属离子),其中该方法采用细菌来源的半乳糖激酶和细菌来源的己糖-1-磷酸尿苷酰转移酶。 本发明还涉及设想用作药物和其它材料的4-位卤代半乳糖的糖链以及该化合物的应用。
    • 2. 发明申请
    • SUGAR CHAIN CONTAINING 4-POSITION HALOGENATED GALACTOSE AND APPLICATION THEREOF
    • 含有4-位羟基糖的糖链及其应用
    • US20090018327A1
    • 2009-01-15
    • US11815329
    • 2006-02-14
    • Shin-Ichiro NishimuraNoriko NagahoriTomoki HamamotoKiyoshi OkuyamaToshitada Noguchi
    • Shin-Ichiro NishimuraNoriko NagahoriTomoki HamamotoKiyoshi OkuyamaToshitada Noguchi
    • C07H5/02C12P19/30
    • C12P19/32C07H15/08
    • The present invention is directed to, for example, an oligosaccharide having at an end thereof a 4-position halogenated galactose residue represented by formula (I): (wherein X represents a halogen atom, and R represents a monosaccharide, an oligosaccharide, or a carrier), a transferase inhibitor containing the oligosaccharide, and a method for inhibiting sugar chain elongation reaction in the presence of glycosyltransferase, the method including employing the inhibitor.The invention also provides a method for producing a 4-position halogenated galactose sugar nucleotide represented by formula (II): (wherein each of R1 to R3 represents a hydroxyl group, an acetyl group, a halogen atom, or a hydrogen atom; X represents a halogen atom; and M represents a hydrogen ion or a metal ion), wherein the method employs bacterium-derived galactokinase and bacterium-derived hexose-1-phosphate uridylyltransferase.The invention is also directed to a sugar chain containing 4-position halogenated galactose envisaged to be employed as drugs and other materials, and to applications of the compound.
    • 本发明涉及例如末端具有由式(I)表示的4-位卤代半乳糖残基的寡糖:(其中,X表示卤素原子,R表示单糖,寡糖,或 载体),含有寡糖的转移酶抑制剂,以及在糖基转移酶存在下抑制糖链延长反应的方法,该方法包括使用该抑制剂。 本发明还提供了由式(II)表示的4-位卤代半乳糖糖核苷酸的制备方法:(式中,R 1〜R 3各自表示羟基,乙酰基,卤素原子或氢原子; X表示 卤素原子; M表示氢离子或金属离子),其中该方法采用细菌来源的半乳糖激酶和细菌来源的己糖-1-磷酸尿苷酰转移酶。 本发明还涉及设想用作药物和其它材料的4-位卤代半乳糖的糖链以及该化合物的应用。
    • 8. 发明授权
    • Process for producing CMP-N-acetylneuraminic acid
    • 制备CMP-N-乙酰神经氨酸的方法
    • US07955825B2
    • 2011-06-07
    • US10521576
    • 2003-01-15
    • Toshitada NoguchiTomoki Hamamoto
    • Toshitada NoguchiTomoki Hamamoto
    • C12P7/40
    • C12N9/1241C12N9/88C12N9/90C12P19/305
    • The present invention is directed to a process for producing CMP-N-acetylneuraminic acid (CMP-NeuAc), comprising adding to the cultured E. coli cells which has been transformed with both the DNA encoding N-acetylglucosamine-6-phosphate 2-epimerase (GlcNAc-6P 2-epimerase) and the DNA encoding N-acetylneuraminic acid synthase (NeuAc synthase) and exhibit activities of N-acetylglucosamine-6-phosphate 2-epimerase and N-acetylneuraminic acid synthase, a phosphate buffer containing baker's yeast cells, CMP, N-acetylglucosamine (GlcNAc), magnesium, xylene, glucose, and CMP-N-acetylneuraminic acid synthase (CMP-NeuAc synthase) to provide a reaction mixture, and allowing the reaction to proceed and produce CMP-N-acetylneuraminic acid (CMP-NeuAc), and wherein the process does not require adding ATP.
    • 本发明涉及一种生产CMP-N-乙酰神经氨酸(CMP-NeuAc)的方法,其包括将已经用编码N-乙酰葡糖胺-6-磷酸2-差向异构酶的DNA转化的培养的大肠杆菌细胞 (GlcNAc-6P 2-差向异构酶)和编码N-乙酰神经氨酸合酶(NeuAc合酶)的DNA,并显示N-乙酰葡糖胺-6-磷酸2-差向异构酶和N-乙酰神经氨酸合酶(含有面包酵母细胞的磷酸盐缓冲液)的活性, CMP,N-乙酰氨基葡萄糖(GlcNAc),镁,二甲苯,葡萄糖和CMP-N-乙酰神经氨酸合成酶(CMP-NeuAc合成酶)以提供反应混合物,并使反应进行并产生CMP- N-乙酰神经氨酸 CMP-NeuAc),并且其中该方法不需要加入ATP。
    • 10. 发明申请
    • Process for Producing Cmp-N-Acetylneuraminic Acid
    • 生产Cmp-N-乙酰神经氨酸的方法
    • US20080070285A1
    • 2008-03-20
    • US10573385
    • 2004-09-21
    • Tomoki HamamotoKuniaki NagaokaToshitada Noguchi
    • Tomoki HamamotoKuniaki NagaokaToshitada Noguchi
    • C12P19/02
    • C12P19/385C12P19/305
    • A method by which high-purity CMP-N-acetylneuraminic acid (HPLC purity, 95% or higher), which has been difficult to obtain with any technique other than chromatography, can be easily obtained in satisfactory yield by a simple operation without the need of chromatography. The process, which is for producing high-purity CMP-N-acetylneuraminic acid (CMP-NeuAc), is characterized by conducting a suitable combination of the following steps (1) to (4). Step 1: a step in which divalent cations are added to a solution containing CMP-NeuAc to thereby precipitate the phosphoric acid, pyrophosphoric acid, and nucleotide which coexist; Step 2: a step in which a phosphatase is added to a solution containing CMP-NeuAc to thereby convert the coexistent nucleotide into nucleoside; Step 3: a step in which an organic solvent is added to precipitate the CMP-NeuAc; and Step 4: a step in which the CMP-NeuAc precipitated is recovered.
    • 可以通过简单的操作容易地以令人满意的产率获得用色谱法以外的任何技术难以获得的高纯度CMP-N-乙酰神经氨酸(HPLC纯度,95%或更高)的方法,而不需要 的色谱。 用于生产高纯度CMP-N-乙酰神经氨酸(CMP-NeuAc)的方法的特征在于进行以下步骤(1)至(4)的适当组合。 步骤1:将二价阳离子加入到含有CMP-NeuAc的溶液中以沉淀磷酸,焦磷酸和共存的核苷酸的步骤; 步骤2:将含有CMP-NeuAc的溶液中加入磷酸酶,从而将共存核苷酸转化为核苷的步骤; 步骤3:加入有机溶剂沉淀CMP-NeuAc的步骤; 步骤4:回收沉淀的CMP-NeuAc的步骤。